Skip to main content
. 2016 Oct 15;7(50):82493–82503. doi: 10.18632/oncotarget.12696

Figure 2. Detection of the anti-FIRs antibodies in the serum of colon cancer patients.

Figure 2

(A) The relative expression of anti-FIRs antibodies in the serum was detected against 2, 10, 50 ng of FIRΔexon2 purified proteins by dot blot analysis. The intensities of the dot signals were quantified by Lumi Vision Imager analysis software (Aisin Seiki Co., Ltd. Aichi, Japan). The relative intensity of the signals was compared between colorectal cancer patients and healthy subjects. (B) The dot blot membranes were stripped and reprobed with anti-FIRs (6B4) antibody for the confirmation of the dose of antigens. Dot blot intensities were standardized by positive control anti-FIRs (6B4) antibody. (C) Dose dependent curves of each patient were shown. (D) The levels of anti-FIRs antibodies in esophageal cancer (EC), colorectal cancer (CC) and were examined by AlphaLISA. Healthy subjects (HS) were as control. P values were calculated by Mann-Whitney U test.